http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
-
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
-
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
-
Kiromic BioPharma (KRBP) Deltacel Receives FDA Fast Track Designation
-
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
-
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
-
Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
-
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
-
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
-
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
-
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
-
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
-
Kiromic BioPharma (KRBP) Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Trial First Three Patients
-
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
-
Kiromic BioPharma (KRBP) Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Trial
-
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
-
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
-
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
-
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
-
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
-
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
-
Kiromic BioPharma (KRBP) Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Trial in Non-Small Cell Lung Cancer
-
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
-
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
-
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
-
Kiromic BioPharma Announces Uplisting to OTCQB Market
-
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
-
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
-
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
-
Kiromic BioPharma (KRBP) Welcomes Two New Directors to its Board
-
Kiromic BioPharma Welcomes Two New Directors to its Board
-
Kiromic BioPharma (KRBP) Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial of Deltacel
-
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
-
Kiromic BioPharma (KRBP) Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
-
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
-
Kiromic BioPharma Announces Reverse Stock Split
-
Kiromic BioPharma (KRBP) Reports Favorable Deltacel Preclinical Pharmacology Results
-
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
-
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
-
Kiromic BioPharma (KRBP) CEO Issues Letter to Stockholders
-
Kiromic BioPharma CEO Issues Letter to Stockholders
-
Kiromic BioPharma (KRBP) Arranges Up to $10 Million Financing
-
Kiromic BioPharma Arranges Up to $10 Million Financing
-
Kiromic BioPharma (KRBP) receives validating written feedback from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel development strategy
-
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, Kiromic, and LifeStance and Encourages Investors to Contact the Firm
-
Kiromic BioPharma (KRBP) Appoints Leonardo Mirandola as Chief Scientific Officer
-
Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer
-
Kiromic BioPharma (KRBP) Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
-
Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
